Argentina’s national health regulator, ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), has prohibited the use, sale, advertising, and distribution of any product claiming to contain retatrutide or retatrutida, citing the lack of approved medicines containing the investigational peptide in the country.
The measure, formalized through Disposition No. 6140/2026, applies nationwide and extends to e-commerce platforms, covering all lots, package sizes, and presentations of products intended for human administration that declare retatrutide as an ingredient. The only exception is for products used in clinical research specifically authorized by ANMAT.
Why ANMAT Took Action
According to the regulator, the decision followed the identification of websites offering products marketed as containing retatrutide. ANMAT stated that no medicinal products containing the compound are currently authorized or commercially available in Argentina.
The agency emphasized that products being sold outside authorized clinical trials lack the regulatory oversight necessary to verify their quality, safety, and efficacy, creating potential health risks for consumers.
A Peptide Under Investigation
Retatrutide has attracted significant attention in the metabolic disease field as an investigational peptide therapy being studied for obesity and type 2 diabetes. ANMAT noted that the compound remains in clinical development and is being investigated for its potential effects in patients with type 2 diabetes and inadequate glycemic control.
The regulator also referenced warnings issued by Brazil’s ANVISA and Paraguay’s DINAVISA regarding products claiming to contain retatrutide.
Despite growing regulatory scrutiny around unauthorized products claiming to contain retatrutide, interest in the investigational peptide remains high due to encouraging clinical data.
Retatrutide is being evaluated as a next-generation triple hormone receptor agonist targeting GLP-1, GIP, and glucagon pathways. In a Phase 2 trial published in The New England Journal of Medicine, participants with obesity who received the highest dose achieved mean weight reductions of up to 24.2% at 48 weeks, while also demonstrating improvements in cardiometabolic markers. Meanwhile, the compound continues to advance through late-stage clinical development for obesity and type 2 diabetes, underscoring why regulators are seeking to curb the proliferation of unapproved products while legitimate research remains ongoing.
What It Means for the Peptide Industry
The decision highlights a growing challenge facing the peptide therapeutics sector: demand for next-generation metabolic treatments is increasing faster than regulatory approvals. As interest grows around experimental incretin-based therapies, health authorities are stepping up enforcement against unapproved products marketed online.
For peptide researchers and industry observers, the announcement serves as a reminder that retatrutide remains an investigational compound and that any legitimate human use must occur within properly authorized clinical studies.